mounjaro - Stock Newsroom

S TOCK newsroom .COM

S&P 500 6,842 +0.87%

DJIA 48,355 +0.93%

Nasdaq 25,100 +0.83%

DAX 23,938 -0.11%

Gold $4,196 +0.16%

Oil $95.65 -1.08%

BTC $72,423 +1.48%

VIX 20.48 -15.65%

EUR/USD 1.1785 -0.02%

ETH $2,220 +0.50%

S&P 500 6,842 +0.87%

DJIA 48,355 +0.93%

Nasdaq 25,100 +0.83%

DAX 23,938 -0.11%

Gold $4,196 +0.16%

Oil $95.65 -1.08%

BTC $72,423 +1.48%

VIX 20.48 -15.65%

EUR/USD 1.1785 -0.02%

ETH $2,220 +0.50%

mounjaro

Eli Lilly GLP-1 Strategy highlighted with Mounjaro and Zepbound products driving obesity and diabetes revenue boom

Pharma & Healthcare·Stocks·USA

Eli Lilly GLP-1 Strategy Boom and Revenue Shock

By Maik Kemper • Mar 24, 2026

Eli Lilly GLP-1 Strategy highlighted with Mounjaro and Zepbound products driving obesity and diabetes revenue boom

Pharma & Healthcare·Stocks·USA

Eli Lilly GLP-1 Strategy Boom and Revenue Shock

By Maik Kemper • Mar 24, 2026

Can Eli Lilly’s GLP-1 boom keep powering the stock as regulation, lawsuits and ETF concentration risks close in? Maik Kemper Editor in Chief Conclusion The…